Sittard/Leiden, The Netherlands, July 10, 2007 - Royal DSM N.V. and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced a non-exclusive PER.C6® research licensing agreement with Moscow, Russia-based Masterclone. Masterclone will use Crucell's technology to develop an undisclosed antibody. No financial details to be disclosed.
